ProPhase Labs, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
ProPhase Labs, Inc. (PRPH) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$3.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-19
- ProPhase Labs, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$3.05M.
- ProPhase Labs, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$5.17M.
- ProPhase Labs, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$6.84M.
- ProPhase Labs, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$4.47M.
- ProPhase Labs, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was $6.27M.
- ProPhase Labs, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was -$2.33M.
- ProPhase Labs, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2019 was -$3.11M.
- ProPhase Labs, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2018 was -$1.57M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.05M 10-Q · filed 2026-08-19 | -$8.23M 10-Q · filed 2026-08-19 | ||||||
| 2026-03-31 | -$5.17M 10-Q/A · filed 2026-07-09 | -$5.35M 10-Q · filed 2026-06-30 | ||||||
| 2025-09-30 | -$6.84M 10-Q · filed 2025-11-19 | -$11.31M derived: sum of 2 quarters · filed 2026-08-19 | -$15.99M 10-Q · filed 2025-11-19 | |||||
| 2025-06-30 | -$4.47M 10-Q · filed 2026-08-19 | -$9.15M 10-Q · filed 2026-08-19 | ||||||
| 2025-03-31 | -$4.68M 10-Q/A · filed 2026-07-09 | |||||||
| 2024-09-30 | -$4.96M 10-Q · filed 2025-11-19 | -$6.59M 10-Q · filed 2024-11-13 | -$10.43M derived: sum of 2 quarters · filed 2025-11-19 | -$15.95M 10-Q · filed 2025-11-19 | -$19.00M 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | -$5.46M 10-Q · filed 2025-08-13 | -$6.15M 10-Q · filed 2024-08-14 | -$10.99M 10-Q · filed 2025-08-13 | -$12.42M 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | -$5.52M 10-Q · filed 2025-05-20 | -$6.26M 10-Q · filed 2024-05-10 | ||||||
| 2023-09-30 | -$5.14M 10-Q · filed 2024-11-13 | -$8.58M derived: sum of 2 quarters · filed 2024-11-13 | -$8.03M 10-Q · filed 2024-11-13 | |||||
| 2023-06-30 | -$3.44M 10-Q · filed 2024-08-14 | -$2.89M 10-Q · filed 2024-08-14 | ||||||
| 2023-03-31 | $550.00K 10-Q · filed 2024-05-10 | |||||||
| 2022-09-30 | $968.00K 10-Q · filed 2023-11-13 | $8.41M derived: sum of 2 quarters · filed 2023-11-13 | $20.91M 10-Q · filed 2023-11-13 | $31.50M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $7.45M 10-Q · filed 2023-08-11 | $19.94M 10-Q · filed 2023-08-11 | $30.53M derived: sum of 3 quarters · filed 2023-08-11 | $26.55M derived: sum of 4 quarters · filed 2023-08-11 | ||||
| 2022-03-31 | $12.49M 10-Q · filed 2023-05-12 | $23.08M derived: sum of 2 quarters · filed 2023-05-12 | $19.11M derived: sum of 3 quarters · filed 2023-05-12 | $17.71M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $10.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $6.61M derived: sum of 2 quarters · filed 2022-11-10 | $5.22M derived: sum of 3 quarters · filed 2022-11-10 | $6.27M 10-K · filed 2022-03-31 | ||||
| 2021-09-30 | -$3.98M 10-Q · filed 2022-11-10 | -$5.37M derived: sum of 2 quarters · filed 2022-11-10 | -$4.32M 10-Q · filed 2022-11-10 | -$5.33M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | -$1.40M 10-Q · filed 2022-08-12 | -$338.00K 10-Q · filed 2022-08-12 | -$1.36M derived: sum of 3 quarters · filed 2022-08-12 | -$1.93M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $1.06M 10-Q · filed 2022-05-13 | $39.00K derived: sum of 2 quarters · filed 2022-05-13 | -$530.00K derived: sum of 3 quarters · filed 2022-05-13 | -$460.00K derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$1.59M derived: sum of 2 quarters · filed 2022-03-31 | -$1.52M derived: sum of 3 quarters · filed 2022-03-31 | -$2.33M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | -$569.00K 10-Q · filed 2021-11-12 | -$499.00K derived: sum of 2 quarters · filed 2021-11-12 | -$1.31M 10-Q · filed 2021-11-12 | -$1.74M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $70.00K 10-Q · filed 2021-08-13 | -$739.00K 10-Q · filed 2021-08-13 | -$1.17M derived: sum of 3 quarters · filed 2021-08-13 | -$1.59M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | -$809.00K 10-Q · filed 2021-05-14 | -$1.24M derived: sum of 2 quarters · filed 2021-05-14 | -$1.66M derived: sum of 3 quarters · filed 2021-05-14 | |||||
| 2019-12-31 | -$427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$855.00K derived: sum of 2 quarters · filed 2021-03-31 | -$3.11M 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | -$428.00K 10-Q · filed 2020-11-19 | -$2.68M 10-Q · filed 2020-11-19 | ||||||
| 2018-12-31 | -$457.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$1.35M derived: sum of 2 quarters · filed 2020-03-26 | -$1.61M derived: sum of 3 quarters · filed 2020-03-26 | -$1.57M 10-K · filed 2020-03-26 | ||||
| 2018-09-30 | -$897.00K 10-Q · filed 2019-11-12 | -$1.16M derived: sum of 2 quarters · filed 2019-11-12 | -$1.11M 10-Q · filed 2019-11-12 | -$1.24M derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2018-06-30 | -$260.00K 10-Q · filed 2018-08-20 | -$216.00K 10-Q · filed 2018-08-20 | -$345.00K derived: sum of 3 quarters · filed 2019-03-26 | -$817.00K derived: sum of 4 quarters · filed 2019-03-26 | ||||
| 2018-03-31 | $43.00K 10-Q/A · filed 2018-08-20 | -$85.00K derived: sum of 2 quarters · filed 2019-03-26 | -$557.00K derived: sum of 3 quarters · filed 2019-03-26 | -$1.44M derived: sum of 4 quarters · filed 2019-03-26 | ||||
| 2017-12-31 | -$128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | -$600.00K derived: sum of 2 quarters · filed 2019-03-26 | -$1.49M derived: sum of 3 quarters · filed 2019-03-26 | -$2.24M 10-K · filed 2019-03-26 | $14.33M 10-K · filed 2018-03-28 | |||
| 2017-09-30 | -$472.00K 10-Q · filed 2018-11-14 | -$1.36M derived: sum of 2 quarters · filed 2018-11-14 | -$2.11M 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | -$886.00K 10-Q · filed 2018-08-20 | -$1.63M 10-Q · filed 2018-08-20 | ||||||
| 2017-03-31 | -$745.00K 10-Q/A · filed 2018-08-20 | $16.93M 10-Q · filed 2018-05-15 | ||||||
| 2016-12-31 | -$4.01M 10-K/A · filed 2018-08-20 | |||||||
| 2015-12-31 | -$2.09M 10-K/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |